AtriCure (NASDAQ:ATRC – Get Free Report) was upgraded by equities researchers at UBS Group to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports. Wall Street Zen cut shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday.